Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors through Efficient Interleukin-2 Gene Transfer in Vaccinated Rats

@article{Iwadate2005RecombinantSV,
  title={Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors through Efficient Interleukin-2 Gene Transfer in Vaccinated Rats},
  author={Yasuo Iwadate and Makoto Inoue and Takashi Saegusa and Yumiko Tokusumi and Hiroaki Kinoh and Mamoru Hasegawa and Masatoshi Tagawa and Akira Yamaura and Hideaki Shimada},
  journal={Clinical Cancer Research},
  year={2005},
  volume={11},
  pages={3821 - 3827}
}
Purpose: Sendai virus (SeV), a murine parainfluenza virus type I, replicates independent of cellular genome and directs high-level gene expressions when used as a viral vector. We constructed a nontransmissible recombinant SeV vector by deleting the matrix (M) and fusion (F) genes from its genome (SeV/ΔMΔF) to enhance its safety. We also estimated the therapeutic efficacy of the novel vector system against a rat glioblastoma model. Experimental Design: We administered the recombinant SeV vector… 
Non‐transmissible Sendai virus encoding granulocyte macrophage colony‐stimulating factor is a novel and potent vector system for producing autologous tumor vaccines
TLDR
The results suggest that the SeV/dF/G vector is a potential candidate for the production of effective autologous GM‐CSF‐transduced tumor vaccines in clinical cancer immune gene therapy.
Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma.
TLDR
Investigation of the therapeutic effects of Sendai virus particles carrying IL-2 gene in a mouse model of angiosarcoma found immunogene therapy with HVJ-E/IL-2 with or without sunitinib could be a promising therapeutic option for cutaneous angiosARcoma.
Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma
TLDR
HVJ-E enhanced effector T cell-mediated anti-tumor immunity induced by IL-2 through inhibition of Treg-mediated immunosuppression, showing promise as an attractive, novel immunogene therapy for malignant glioma.
New cancer therapy using genetically-engineered oncolytic Sendai virus vector.
  • H. Kinoh, M. Inoue
  • Biology, Medicine
    Frontiers in bioscience : a journal and virtual library
  • 2008
TLDR
The vector selectively spreads to tumor cells in tumor-protease dependent manner and demonstrates the antitumor effects in solid tumors, indicating the value of selective targeting and killing of tumors by recombinant SeV technology.
Synergistic effect of non‐transmissible Sendai virus vector encoding the c‐myc suppressor FUSE‐binding protein‐interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma
TLDR
SeV/ΔF/FIR plus cisplatin will be an attractive modality against HMPM in the future and demonstrated significant tumor reduction and improvement in survival rate in an animal model.
Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-β gene.
TLDR
Results suggest that BioKnife-IFNβ may have significant potential to improve the survival of GM patients in a clinical setting.
Sendai Virus-Based Oncolytic Gene Therapy
TLDR
The use of adenoviral gene therapy in an 18-year-old with an inherited enzyme deficiency at the University of Pennsylvania’s Institute for Human Gene Therapy resulted in the death of the patient 4 days after the injection of the vectors into the liver in 1999, and the low effec‐ tiveness of nonviral vectors in gene transduction remains a serious problem.
Chapter 9 Sendai Virus-Based Oncolytic Gene Therapy
The first gene therapy that was used on humans was performed for adenosine deaminase (ADA) deficiency in 1990 [1]. In the early days of gene therapy, it was thought to be a break‐ through in the
Sendai virus-mediated gene transfer of GDNF reduces AIF translocation and ameliorates ischemic cerebral injury
TLDR
It is demonstrated that SeV vector-mediated gene transfer of GDNF effectively reduced ischemic infarct volume after tMCAO and extended the therapeutic time window compared with previous viral vectors, and that promoting neuronal survival ofGDNF might be related to the reduction of AIF nuclear translocation.
Oncolysis by paramyxoviruses: preclinical and clinical studies
TLDR
In general, preclinical studies and phase 1–3 clinical trials yield very encouraging results and warrant continued research of oncolytic paramyxoviruses as a particularly valuable addition to the existing panel of cancer-fighting approaches.
...
1
2
3
4
...

References

SHOWING 1-10 OF 27 REFERENCES
Recombinant Sendai virus vectors for activated T lymphocytes
TLDR
It is proposed that the SeV vector system may prove to be a potentially important alternative in the area of T-cell-directed gene therapy used in the clinical setting.
Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
TLDR
Sequential magnetic resonance image monitoring showed that the combinatory therapy consisting of intracerebral transplantation of IL-2-producing rat gliosarcoma 9L (9L/IL-2) cells and s.c. immunization of irradiated whole tumor cell vaccine is effective for recruiting activated T cells into the brain tumor site and could be a potential therapy for brain tumors.
A New Sendai Virus Vector Deficient in the Matrix Gene Does Not Form Virus Particles and Shows Extensive Cell-to-Cell Spreading
TLDR
SeV/ΔM is a novel type of vector with the characteristic features of loss of virus particle formation and gain of cell-to-cell spreading via a mechanism dependent on the activation of the fusion protein.
Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells
TLDR
Findings show that SeV could prove to be a promising vector for efficient gene transfer to CB HSCs, while preserving their ability to reconstitute the entire hematopoietic series.
Evaluation of the bystander effect in experimental brain tumors bearing herpes simplex virus-thymidine kinase gene by serial magnetic resonance imaging.
TLDR
The present results show that the bystander effect is clearly observed in vivo in a TK percentage-dependent manner, and a population of more than 25% of TK-positive cells is required for complete tumor elimination.
Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure.
TLDR
This work represents the first report of SeV-mediated gene transfer to ocular tissue, and identifies recombinant SeV as a new tool for studies of retinal gene transfer and gene therapy.
Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors
TLDR
Results showed that systemic immune responses to brain tumor were induced in an immunologically privileged site by concurrent s.c. inoculation of the same tumors that produce IL-2.
A Cytoplasmic RNA Vector Derived from Nontransmissible Sendai Virus with Efficient Gene Transfer and Expression
TLDR
A virion from defective cDNA of Sendai virus (SeV) that is capable of self-replication but incapable of transmissible-virion production is recovered and it is suggested that this vector has great potential for use in human gene therapy and vaccine delivery systems.
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.
TLDR
The adjuvant treatment in the treatment of 248 patients with newly diagnosed, previously untreated glioblastoma multiforme improved neither time to tumor progression nor overall survival time, although the feasibility and good biosafety profile of this gene therapy strategy were further supported.
Efficient gene transfer to airway epithelium using recombinant Sendai virus
TLDR
It is shown that recombinant Sendai virus (SeV) produces efficient transfection throughout the respiratory tract of both mice and ferrets in vivo, as well as in freshly obtained human nasal epithelial cells in vitro.
...
1
2
3
...